AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by State Street Corp

State Street Corp lessened its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 6.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 906,182 shares of the biotechnology company's stock after selling 60,670 shares during the period. State Street Corp owned 2.98% of AnaptysBio worth $30,357,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of ANAB. Frazier Life Sciences Management L.P. increased its position in AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company's stock worth $54,270,000 after purchasing an additional 1,265,891 shares during the last quarter. FMR LLC increased its holdings in shares of AnaptysBio by 15.3% during the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company's stock worth $110,857,000 after buying an additional 438,557 shares during the last quarter. Jennison Associates LLC acquired a new stake in shares of AnaptysBio during the 3rd quarter worth approximately $8,874,000. Victory Capital Management Inc. raised its position in shares of AnaptysBio by 677.9% during the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company's stock valued at $7,948,000 after buying an additional 206,750 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company's stock worth $15,927,000 after acquiring an additional 168,813 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ANAB. Wells Fargo & Company decreased their price target on AnaptysBio from $56.00 to $40.00 and set an "overweight" rating on the stock in a research note on Thursday, December 12th. BTIG Research cut shares of AnaptysBio from a "buy" rating to a "neutral" rating in a research report on Monday, December 2nd. UBS Group upped their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a research report on Wednesday, October 30th. HC Wainwright cut shares of AnaptysBio from a "buy" rating to a "neutral" rating and dropped their price target for the company from $52.00 to $19.00 in a research report on Wednesday, December 11th. Finally, Guggenheim lowered their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a "buy" rating for the company in a research report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $41.45.

Insider Buying and Selling at AnaptysBio

In related news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the transaction, the insider now owns 15,398 shares of the company's stock, valued at $595,440.66. This represents a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 33.70% of the stock is owned by corporate insiders.

AnaptysBio Stock Down 3.0 %

ANAB stock traded down $0.45 during midday trading on Friday, hitting $14.55. The company's stock had a trading volume of 1,588,565 shares, compared to its average volume of 389,269. The firm has a 50-day simple moving average of $23.87 and a 200-day simple moving average of $29.21. The firm has a market capitalization of $442.74 million, a P/E ratio of -2.39 and a beta of -0.11. AnaptysBio, Inc. has a 52-week low of $14.19 and a 52-week high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million for the quarter, compared to analysts' expectations of $7.92 million. On average, sell-side analysts expect that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.